Table 3 Chemotherapy and concomitant medications by treatment group
Nadroparin (n = 769) % (n) | Placebo (n = 381) % (n) | P-value (two tailed) | |
|---|---|---|---|
Chemotherapy regimen containinga: | |||
5-Fluorouracil | 37.1 (285) | 39.6 (151) | 0.40 |
Cisplatin | 23.0 (177) | 22.6 (86) | 0.87 |
Gemcitabine | 20.3 (156) | 22.6 (86) | 0.37 |
Oxaliplatin | 18.6 (143) | 23.4 (89) | 0.06 |
Docetaxel | 18.5 (142) | 17.6 (67) | 0.72 |
Carboplatin | 15.5 (119) | 14.4 (55) | 0.64 |
Irinotecan | 12.5 (96) | 10.8 (41) | 0.40 |
Vinca alkaloids | 11.7 (90) | 7.1 (27) | 0.01 |
Capecitabine | 7.9 (61) | 7.9 (30) | 0.97 |
Epirubicin | 7.0 (54) | 6.3 (24) | 0.65 |
Etoposide | 5.3 (41) | 4.5 (17) | 0.53 |
Cyclophosphamide | 4.3 (33) | 4.7 (18) | 0.74 |
Liposomal doxorubicin | 3.8 (29) | 2.9 (11) | 0.44 |
Adriamycin | 3.3 (25) | 5.0 (19) | 0.15 |
Trastuzumab | 3.0 (23) | 2.4 (9) | 0.54 |
Cetuximab | 0.9 (7) | 0.8 (3) | 0.83 |
Bevacizumab | 0.5 (4) | 0.5 (2) | 0.99 |
Concomitant Medication b | |||
Steroids | 76.2 (586) | 78.7 (300) | 0.34 |
G-CSF | 15.1 (116) | 15.5 (59) | 0.86 |
NSAID | 11.2 (86) | 12.9 (49) | 0.41 |
Erythropoietin | 7.4 (57) | 8.7 (33) | 0.46 |
Blood and related products | 2.7 (21) | 3.9 (15) | 0.27 |
Aspirin | 2.2 (17) | 2.1 (8) | 0.90 |